iShares Nasdaq Biotechnology (IBB) Poised to Open Up Over 2%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Gilead (GILD) Harvoni/Sovaldi Label Changes Are Not Meaningful, Baird Says
March 23, 2015 6:54 AM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) following Harvoni/Sovaldi labeling changes. The firm reiterated an Outperform rating and price target of $126, saying the changes are not meaningful.
Skorney commented, "No change to view following Harvoni/Sovaldi labeling... More
Biogen (BIIB) Price Target Lifted to $532 at Leerink Partners on Strong Showing for BIIB037
March 20, 2015 10:28 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and lifted his price target on Biogen (NASDAQ: BIIB) to $532.00 (from $475.00)
Schwartz said, "This morning at the ADPD15 meeting, BIIB reported better than expected results from BIIB037s Ph. Ib trial on both... More
iShares Nasdaq Biotechnology (IBB) Makes Green to Red Reversal
March 20, 2015 10:28 AM EDTiShares Nasdaq Biotechnology (NASDAQ: IBB) Makes Green to Red Reversal
... MoreBiogen (BIIB) PT Lifted to $512 at Citi; Questions Remain on Dose/Saftey
March 20, 2015 9:39 AM EDTCiti reiterated a Buy rating and boosted its price target on Biogen (NASDAQ: BIIB) to $512.00 (from $410.00) following solid potency data on BIIB037, although main question in dose/safety.
"The only question is safety as 32% of patients on the high does... More
